Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

HMR begins phase II trial with GA-EPO

Dec. 8, 1997

Sanofi in-licenses antidiabetic drug from Bayer

Dec. 4, 1997

New inhibitor of inflammatory bone resorption presented at Tokyo congress

Dec. 4, 1997

Vitronectin receptor antagonists described by Hoechst

Dec. 4, 1997

Bayer develops CETP inhibitors

Dec. 4, 1997

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Dec. 3, 1997

Mechanism of renoprotective effects of ACE inhibitors in diabetic nephropathy

Dec. 3, 1997

Reduced PSF expression associated with development of vascular lesions

Dec. 3, 1997

Takeda discloses new series of prolactin secretion inhibitors

Dec. 3, 1997

Maillard reaction inhibitors from Kissei

Dec. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...